Savvy Trades and Investments

[dmmm]

MPH The 2023 patent is for a treatment procedure, of which aggrastat is one component. I think when folks say "expanded use" they are referring to an FDA approval to use this new procedure. If you read the actual annual report on sedar it is quite clear that they are making money only from sales of aggrastat. I don't really understand how a company with no U.S. operations would make money off of a treatment procedure. Licensing the patent to medical service providers? It's quite clear they don't do that. I'm not a huge fan of this company so I could go on but all I want to say is I think a little more skepticism is in order.

ref http://www.drugs.com/availability/generic-aggrastat.html

edited: I think they do their own research, outside the US